Literature DB >> 22203600

A novel agent effective against Clostridium difficile infection.

Sofya Dvoskin1, Wei-Chu Xu, Neal C Brown, Ivan B Yanachkov, Milka Yanachkova, George E Wright.   

Abstract

N(2)-(3,4-Dichlorobenzyl)-7-(2-[1-morpholinyl]ethyl)guanine (MorE-DCBG, 362E) is a synthetic purine that selectively inhibits the replication-specific DNA polymerase of Clostridium difficile. MorE-DCBG and its analogs strongly inhibited the growth of a wide variety of C. difficile strains. When administered orally in a hamster model of C. difficile-specific colitis, 362E was as effective as oral vancomycin, the current agent of choice for treating severe forms of the human disease.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203600      PMCID： PMC3294905          DOI： 10.1128/AAC.06097-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Active site directed inhibitors of replication-specific bacterial DNA polymerases.

Authors:  George E Wright; Neal C Brown; Wei-Chu Xu; Zheng-Yu Long; Chengxin Zhi; Joseph J Gambino; Marjorie H Barnes; Michelle M Butler
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

2.  Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Yuejin Li; Michael J Pultz; Michelle M Riggs; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 3.  Clostridium difficile--associated diarrhea.

Authors:  S Johnson; D N Gerding
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

Review 4.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity.

Authors:  Wei-Chu Xu; George E Wright; Neal C Brown; Zheng-Yu Long; Cheng-Xin Zhi; Sofya Dvoskin; Joseph J Gambino; Marjorie H Barnes; Michelle M Butler
Journal:  Bioorg Med Chem Lett       Date:  2011-05-30       Impact factor: 2.823

6.  Clostridium difficile DNA polymerase IIIC: basis for activity of antibacterial compounds.

Authors:  Andrea Torti; Andrea Lossani; Lida Savi; Federico Focher; George Edward Wright; Neal Curtis Brown; Wei-Chu Xu
Journal:  Curr Enzym Inhib       Date:  2011-10

Review 7.  Update on the changing epidemiology of Clostridium difficile-associated disease.

Authors:  Lynne V McFarland
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-01

8.  Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Michelle M Nerandzic; Greg S Bobulsky; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

9.  Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.

Authors:  Efi Kokkotou; Alan C Moss; Athanasios Michos; Daniel Espinoza; Jeffrey W Cloud; Nasima Mustafa; Michael O'Brien; Charalabos Pothoulakis; Ciarán P Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

Review 10.  Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.

Authors: 
Journal:  Drugs R D       Date:  2010
  10 in total
  7 in total

1.  Efficacy of LFF571 in a hamster model of Clostridium difficile infection.

Authors:  Anna Trzasko; Jennifer A Leeds; Jens Praestgaard; Matthew J Lamarche; David McKenney
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Comparative Studies to Uncover Mechanisms of Action of N-(1,3,4-Oxadiazol-2-yl)benzamide Containing Antibacterial Agents.

Authors:  George A Naclerio; Kenneth I Onyedibe; Caroline W Karanja; Uma K Aryal; Herman O Sintim
Journal:  ACS Infect Dis       Date:  2022-03-17       Impact factor: 5.578

3.  Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile.

Authors:  Erika van Eijk; Ilse M Boekhoud; Ed J Kuijper; Ingrid M J G Bos-Sanders; George Wright; Wiep Klaas Smits
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 4.  DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.

Authors:  Erika van Eijk; Bert Wittekoek; Ed J Kuijper; Wiep Klaas Smits
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

5.  In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Sci Rep       Date:  2021-03-29       Impact factor: 4.379

Review 6.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 7.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.